Anti-cancer agents selected for the study included the established oral alkylating drug Temozolomide (TMZ) (61), two histone deacetylase (HDAC) inhibitors, Vorinostat and Entinostat, which have been examined in early-phase clinical trials (21, 45), and the neuroactive peptide Apamin, proposed as a blocker of invasiveness based on in vitro assays (43). This evidence concerns the gene HDAC9 and cancer.